All In Biotech

Drug Trial Radar · NCT02908906

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

63723283LUC1001: A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

234

Actual

Start

Nov 21, 2016

Primary completion

Nov 17, 2023

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Primary purpose of this study is to identify the recommended Phase 2 dose \[RP2D(s)\] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, and high-level microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) in Part 2, to determine one or more additional RP2Ds in Parts 3 and 4.

Conditions

  • Neoplasms

Interventions

  • JNJ-63723283Drug

    JNJ-63723283 will be administered by IV infusion or SC injection or infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Frequency and Severity of Dose-Limiting Toxicity (DLT)Time frame: Up to 2 years 6 months
  2. Part 2: Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Subjects With Selected Advanced Solid TumorsTime frame: Up to 2 years 6 months
  3. Parts 3 and 4: Area Under the Serum Concentration Versus Time Curve from Time Zero to Dosing Interval (AUC [0-tau])Time frame: Up to 2 years 6 months

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    St Louis, Missouri

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Chisinau, Moldova

  • Site not named

    Bialystok, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Moscow, Russia

  • Site not named

    Pyatigorsk, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Badalona, Spain

  • Site not named

    Barcelona, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Málaga, Spain

  • Site not named

    Pamplona, Spain

  • Site not named

    Seville, Spain

  • Site not named

    Valencia, Spain

  • Site not named

    Gothenburg, Sweden

  • Site not named

    Glasgow, United Kingdom

  • Site not named

    London, United Kingdom

  • Site not named

    Manchester, United Kingdom

  • Site not named

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.